Teva Pharmaceutical Industries Stock Number Of Shares Shorted
| TEV Stock | EUR 21.20 0.70 3.41% |
Teva Pharmaceutical Industries fundamentals help investors to digest information that contributes to Teva Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharmaceutical stock.
Teva |
Teva Pharmaceutical Industries Company Number Of Shares Shorted Analysis
Teva Pharmaceutical's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Teva Pharmaceutical Industries has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The number of shares shorted for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Teva Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.17 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 49.70 % | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.61 X | |||
| Revenue | 14.93 B | |||
| Gross Profit | 6.97 B | |||
| EBITDA | (827 M) | |||
| Net Income | (2.35 B) | |||
| Cash And Equivalents | 1.97 B | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 19.1 B | |||
| Debt To Equity | 184.30 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 7.11 X | |||
| Cash Flow From Operations | 1.59 B | |||
| Earnings Per Share | (1.96) X | |||
| Price To Earnings To Growth | 0.75 X | |||
| Target Price | 11.47 | |||
| Number Of Employees | 34 K | |||
| Beta | 1.22 | |||
| Market Capitalization | 10.47 B | |||
| Total Asset | 44.01 B | |||
| Five Year Return | 3.24 % | |||
| Net Asset | 44.01 B |
About Teva Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.